Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

r share, basic, and $1.21 per share, diluted, compared to a net income of $0.97 per share, basic, and $0.95 per share, diluted, for the same period in 2006.

The primary drivers of the change in net income for the fourth quarter were the effects of decreased operating income discussed above, partially offset by increased interest income and a lower effective tax rate. Net income for the twelve month period increased primarily due to higher net sales and higher interest income, partially offset by increased operating expenses.

Operating Highlights

During the three and twelve months ended December 31, 2007, net sales of Vancocin increased 24.0 percent and 22.3 percent, respectively, compared to the same periods in 2006. The three and twelve month increases resulted from an increase of units sold, the impact of a price increase during 2007 and wholesaler inventory levels which were stable in 2007 compared to decreased levels in 2006.

The cost of sales for Vancocin for the three months ended December 31, 2007 remained consistent from the three months ended December 31, 2006 at $2.0 million. For the twelve months ended December 31, 2007, the cost of sales decreased $10.1 million to $8.9 million from $19.0 million in the same period in 2006. This decrease primarily results from the sale of units during the first half of 2007, which were manufactured by NPI Pharmaceuticals (formerly OSG Norwich) and carried a lower inventory cost than the units sold during the first half of 2006 that were manufactured by Eli Lilly & Co.

The total remaining costs and expenses associated with operating income were $26.6 million and $11.5 million, for the fourth quarter of 2007 and 2006, respectively, and $79.0 million and $49.4 million, for the twelve months of 2007 and 2006, respectively. These increases are primarily due to research and development costs, increased medical education and legal costs as well as an increase in stock compensation expense.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
10. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
11. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... The impact of the Trivedi Master ... of the public and is likely to cause further, ... and June. From March 21st to March 31st, ... "Special Prayers." More than 600 people participated in the ... and have reported intense experiences that they attest have ...
(Date:4/25/2015)... April 25, 2015 The URO CENTER of ... has been chosen by the New York Academy of Medicine ... medicine in the field of Urology. , Dr. Ferdinand Valentine, ... speciality, Genito-Urinary diseases. He was a man of rare ... of urology. Not only did he devote his life ...
(Date:4/24/2015)... 2015 Bird B Gone, the leader in ... offers a complete line of bird control solutions to address ... New Flu Strains Threaten Pacific, Central and Mississippi Farms , ... , a number of highly pathogenic avian flus in the ... often spread when wild birds enter poultry farms. The USDA ...
(Date:4/24/2015)... Ryadon is a leading manufacturer of custom ... services to complement any custom hardware requirements you may ... be offered on all heavy duty drawer slides ( ... discount - Order 20+: Receive 20% discount , Industries ... Furniture ,Drawer Slides, Inc. ...
(Date:4/24/2015)... 2015 The 1975 have had ... across the globe to theaters, festivals and TV performances. Now ... partnered with their label, Dirty Hit Records, to provide clean ... the newly launched Cadence & Cause website, this ... on vinyl and a signed photo card. Entries from ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... 28 Nutrition 21, Inc.,(Nasdaq: NXXI ), ... consumers manage blood sugar levels, improve cardiovascular health,enhance ... two new,additions to its Iceland Health(R) brand portfolio: ... Plus SLEEP Support.,Formulated with omega-3 fish oil and ...
... Noor came to,the attention of the Battalion Commander of ... Brigade Combat Team through an,unfortunate shooting incident from a ... little girl,s uncle. The initial diagnosis made by Lt.,Col. ... blind,due to a birth defect that resulted in poorly ...
... 28 OrbusNeich today announced that it,has received approval ... R stent in Taiwan., The Genous stent is ... cells (EPCs) circulating in the bloodstream. When,attracted to the ... shown to,quickly form a healthy layer of endothelium that ...
... 28 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... New Drug Application (NDA) for oxybutynin,chloride topical gel ... U.S. Food,and Drug Administration (FDA). Watson is seeking ... hydrochloride for the treatment of,overactive bladder (OAB)., ...
... account for nearly all of the increase in U.S. singleton ... national birth data. , Between 1996 and 2004 there ... 92 percent of those infants were delivered by a cesarean ... of Dimes and the U.S. Centers for Disease Control and ...
... 27 It is estimated that there were ... Did you know that,African-American women have a 50 ... A new campaign, One4One, is empowering women to,help ... increase cervical,cancer education programs for women in multicultural ...
Cached Medicine News:Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 2Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 3Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 4Health News:Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger 2Health News:OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 3Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 4Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 5Health News:C-sections a critical factor in preterm birth increase 2
(Date:4/24/2015)... , April 24, 2015 Hi-Tech Pharmaceuticals ... was not the product of reliable scientific principles ... reliable basis for allegations of adulteration. The FDA ... a false premise, or misguided hope, that Methylphenylethylamine ... studies are contradicted by multiple other studies and ...
(Date:4/24/2015)... T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), a ... products and a licensed producer ("LP") to cultivate marijuana ... Canada ) ("MMPR"), is pleased to announce that ... the transaction announced on March 11, 2015 with Medna ... a total of 20,156,790 common shares of T-Bird (45% ...
(Date:4/24/2015)... , April 24, 2015  Elekta has CE marked ... treatment planning system , enabling European clinics to deliver ... treatment techniques including advanced 3D planning, IMRT, VMAT and ... Monaco ® ... improved workflow efficiency. Advancements in 3D planning as well ...
Breaking Medicine Technology:Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Elekta CE marks for Monaco v5.10 treatment planning system 2
... Treatment of Inflammatory ... ... MOUNTAIN VIEW, Calif., May 13 ChemoCentryx, Inc., today,announced the ... small molecule compound designed to specifically,target the CCR1 chemokine receptor which ...
... New soluble polymer material,designed to stop bone bleeding ... new animal study just published in the Annals of ... recently published,research showing that the use of the new ... from the Medical University of South Carolina at Charleston,and ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 2Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: